Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Anti-IL17 in New-onset Type 1 Diabetes: a Randomized, Double-blind, Placebo-controlled Trial

NCT04589325 is registered in ClinicalTrials.gov with Göteborg University as lead sponsor.

NCT NCT04589325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04589325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Anti-IL17 in New-onset Type 1 Diabetes: a Randomized, Double-blind, Placebo-controlled Trial
Lead sponsor
Göteborg University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 9, 2022
Completion date
December 31, 2027
Enrollment
127 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

type1 diabetes mellitus